Technology Bundle ID: TAB-2603

Multiplex Assay for Detection of Dengue Virus

Request More Info
Licensing Contact:
Primary Inventors: 
Jorge Munoz-Jordan (CDC)
Co-Inventors: 
Edgardo Vergne (CDC), Gilberto Santiago (CDC)
Development Status: 
  • In vitro data available
  • In situ data available (on-site)
Institute or Center: 
CDC

Dengue virus (DENV) is the cause of dengue illness (dengue fever, dengue hemorrhagic fever, and dengue shock syndrome). CDC researchers have developed a RT-PCR multiplex assay that, prior to sero-conversion, selectively detects dengue virus in biological or other fluid media, such as whole blood, plasma, or serum. The primers and probes from this assay are sufficiently specific to amplify and detect all four DENV serotypes. This FDA-approved technology may provide an improved method for rapid and accurate serotyping of dengue virus in clinical and research settings.

Applications:
  • Rapid, simple and accurate dengue virus (DENV) serotype identification
  • Diagnostic tool for clinical or research settings
Advantages:
  • Increased sensitivity and efficiency compared to current antigen-based assays and single reaction real-time RT-PCR analyses
  • Addresses need for accurate molecular diagnosis of DENV
  • FDA approved technology

Patents

PCT Application PCT/US2012/061828
Filed on 2012-10-25
US Application 61/554,126
Filed on 2011-11-01
US Pat 10,563,269

Issued 2020-02-18
US Pat 9,657,361

Issued 2017-05-23

Publications

Munoz-Jordan JL, et al.
PMID 23632064
Santiago GA, et al.
PMID 23875046

Updated

Aug 2, 2013

Data Source: 
tts